References
- Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol 2012; 12:253 - 68; http://dx.doi.org/10.1038/nri3175; PMID: 22437938
- Suttmann H, Riemensberger J, Bentien G, Schmaltz D, Stöckle M, Jocham D, et al. Neutrophil granulocytes are required for effective Bacillus Calmette-Guérin immunotherapy of bladder cancer and orchestrate local immune responses. Cancer Res 2006; 66:8250 - 7; http://dx.doi.org/10.1158/0008-5472.CAN-06-1416; PMID: 16912205
- de Boer EC, de Jong WH, van der Meijden AP, Steerenberg PA, Witjes F, Vegt PD, et al. Leukocytes in the urine after intravesical BCG treatment for superficial bladder cancer. A flow cytofluorometric analysis. Urol Res 1991; 19:45 - 50; http://dx.doi.org/10.1007/BF00294021; PMID: 2028562
- Ethuin F, Gérard B, Benna JE, Boutten A, Gougereot-Pocidalo MA, Jacob L, et al. Human neutrophils produce interferon gamma upon stimulation by interleukin-12. Lab Invest 2004; 84:1363 - 71; http://dx.doi.org/10.1038/labinvest.3700148; PMID: 15220936
- Jinesh GG, Chunduru S, Kamat AM. Smac mimetic enables the anticancer action of BCG-stimulated neutrophils through TNF-alpha but not through TRAIL and FasL. J Leukoc Biol 2012;
- Kemp TJ, Ludwig AT, Earel JK, Moore JM, Vanoosten RL, Moses B, et al. Neutrophil stimulation with Mycobacterium bovis bacillus Calmette-Guerin (BCG) results in the release of functional soluble TRAIL/Apo-2L. Blood 2005; 106:3474 - 82; http://dx.doi.org/10.1182/blood-2005-03-1327; PMID: 16037389
- Fulda S, Vucic D. Targeting IAP proteins for therapeutic intervention in cancer. Nat Rev Drug Discov 2012; 11:109 - 24; http://dx.doi.org/10.1038/nrd3627; PMID: 22293567